Cidara Therapeutics Inc (CDTX)

Apr 01, 2025

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan

Apr 01, 2025

Apr 01, 2025

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan

Apr 01, 2025

Mar 25, 2025

(CDTX) Investment Analysis - news.stocktradersdaily.com

Mar 25, 2025

Mar 24, 2025

Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch

Mar 24, 2025

Mar 21, 2025

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - Yahoo Finance

Mar 21, 2025

Mar 19, 2025

Cidara Therapeutics to Participate in World Health - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan

Mar 19, 2025

Mar 19, 2025

Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World

Mar 19, 2025

Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire

Mar 18, 2025

Mar 18, 2025

Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan

Mar 18, 2025

Mar 17, 2025

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire

Mar 17, 2025

Mar 17, 2025

Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan

Mar 17, 2025

Mar 16, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World

Mar 16, 2025

Mar 14, 2025

(CDTX) Long Term Investment Analysis - Stock Traders Daily

Mar 14, 2025

Mar 14, 2025

Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 14, 2025

Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India

Mar 13, 2025

Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India

Mar 13, 2025

Mar 13, 2025

Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 13, 2025

Mar 13, 2025

HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World

Mar 13, 2025

Mar 12, 2025

Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq

Mar 12, 2025

Mar 12, 2025

Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha

Mar 12, 2025

Mar 12, 2025

Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks

Mar 12, 2025

Mar 12, 2025

Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada

Mar 12, 2025

Mar 12, 2025

FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World

Mar 12, 2025

Mar 12, 2025

Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks

Mar 12, 2025

Mar 11, 2025

HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World

Mar 11, 2025

Mar 10, 2025

Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks

Mar 10, 2025

Mar 10, 2025

Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks

Mar 10, 2025

Mar 10, 2025

Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Mar 10, 2025

Mar 09, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 09, 2025

Mar 08, 2025

Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing - TipRanks

Mar 08, 2025

Mar 07, 2025

Cidara Therapeutics Advances with Strong Financial Backing - TipRanks

Mar 07, 2025

Mar 07, 2025

Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) - Defense World

Mar 07, 2025

Mar 06, 2025

Cidara Therapeutics: Q4 Earnings Snapshot - Barchart

Mar 06, 2025

Mar 06, 2025

Cidara Therapeutics reports wider Q4 loss, shares dip - Investing.com

Mar 06, 2025

Mar 06, 2025

Cidara Therapeutics reports wider Q4 loss, shares dip By Investing.com - Investing.com South Africa

Mar 06, 2025

Mar 06, 2025

Cidara Therapeutics: Q4 Earnings Snapshot -March 06, 2025 at 05:03 pm EST - Marketscreener.com

Mar 06, 2025

Mar 06, 2025

Cidara Therapeutics Completes Enrollment in Phase 2b NAVIGATE Trial and Secures $105 Million in Financing - Nasdaq

Mar 06, 2025

Mar 06, 2025

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 06, 2025

Mar 06, 2025

Can Cidara's $196M War Chest and 5,000-Patient Trial Transform Flu Prevention? - StockTitan

Mar 06, 2025